Related Experiment Video
Updated: May 17, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Kenneth C Anderson1, Melissa Alsina, William Bensinger
1Dana-Farber/Brigham and Women's Cancer Center.
Journal of the National Comprehensive Cancer Network : JNCCN
|October 12, 2012
Summary
New NCCN Guidelines offer updated management strategies for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Key changes include novel therapies, revised response criteria, and peripheral neuropathy management.
Area of Science:
- Hematology
- Oncology
- Clinical Guidelines
Background:
- Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma requires updated management protocols.
- The NCCN Guidelines provide essential updates for clinicians.
Purpose of the Study:
- To highlight key changes in the NCCN Guidelines for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma.
- To inform clinicians about novel therapeutic options and updated criteria.
Main Methods:
- Review of recent clinical advancements and consensus recommendations.
- Inclusion of data from the sixth international workshop on Waldenström's Macroglobulinemia.
Main Results:
- Novel therapeutic regimens are now recommended for primary and salvage therapy.
- Updated response categories and criteria are incorporated.
- A dedicated section on peripheral neuropathy management is included.
Conclusions:
- The updated NCCN Guidelines provide a comprehensive framework for managing Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma.
- These insights emphasize the integration of novel agents and refined assessment methods.
